- 11 hrs ago Padma Awards 2022 Winners: Complete List Of Recipients Of The Prestigious Government Honour
- 12 hrs ago Expert Opinion: Mental Health And Behavioural Issues In Female Victims Of Violence Or Sexual Assault
- 21 hrs ago Pisces Horoscope 2022: Yearly Astrological Predictions About Life, Love, Career, Health And More
- 22 hrs ago Neglected Infectious Diseases May Be Tomorrow's Pandemic: Bharat Biotech Chief Dr Krishna Ella
- Technology Amazon Accessories Days Sale: Discount Offers On Headphones, Data Cards, Hard disk, Mouse, And More
- News Tatas take first step in Air India, to introduce ‘enhanced meal service’ in 4 flights on Thu
- Movies Melody Song Of The Year From Mahesh Babu’s Sarkaru Vaari Paata Will Be Out On February 14
- Sports India ODI, T20I Squads Against WI: Rohit to lead, Kuldeep, Bishnoi in; Bumrah, Shami rested, Ashwin dropped
- Finance Motilal Oswal Recommends To Buy This Technology Stock For 29% Return
- Automobiles Tork Kratos & Kratos R Electric Motorcycles Launched In India: Prices Start From Rs 1.07 Lakh
- Education Republic Day 2022: Interesting Facts About Republic Day Parade
- Travel National tourism Day 2022: Explore South India And Reclaim Your Post-Lockdown Freedom
The Indian Council of Medical Research (ICMR)'s National Task Force for COVID-19 has decided against including antiviral drug Molnupiravir in the Clinical Management Protocol for COVID-19 as of now, official sources said on Tuesday.
The experts of the task force cited safety concerns and argued that Molnupiravir was not of much benefit in Covid treatment to arrive at the decision in a meeting held on Monday.
According to the Health Ministry, Molnupiravir is an antiviral drug that inhibits SARS-CoV-2 replication by viral mutagenesis. This anti-Covid pill got the Drug Regulator General of India's approval on December 28 for restricted use in emergencies.
"Members of the National Task Force for COVID-19 were not in favour of including the drug in the national treatment guidelines citing that it does not have much benefit in the treatment of coronavirus infection and that there were safety concerns," an official source told PTI.
Indian Council of Medical Research (ICMR) chief Dr Balram Bhargava had last week said that Molnupiravir has major safety concerns. He added that WHO and the UK have not included it for treatment.
"We have to remember that this drug has major safety concerns. It can cause teratogenicity, mutagenicity and cartilage damage. It can damage the muscles also.
"Contraception will have to be done for three months for male and female if this drug is given because the child born could be problematic due to teratogenic influence," he had said.
The UK Medicines and Healthcare products Regulatory Agency had on December 4 granted approval for Molnupiravir under special conditions for treatment of mild to moderate COVID-19 in adults who have at least one risk factor for developing severe illness.
USFDA on December 23 granted Emergency Use Authorisation for the drug for treating mild-to-moderate COVID-19 in adults at high risk for progression to severe disease, including hospitalization or death, and for whom alternative treatment options are not accessible or clinically appropriate.
According to conditions, the drug should be sold by retail only under the prescription of medical specialists and the recommended dose should be 800 mg twice daily for five days.
- healthCOVID Antiviral Drug Molnupiravir Has Major Safety Concerns: ICMR Chief Dr Balram Bhargava
- disorders cureCOVID Antiviral Oral Pill Molnupiravir: Know Price, Dosage, Side Effects And Other Details
- healthSun Pharma Gets DCGI Nod To Market Molnupiravir For COVID-19 Treatment
- healthPanel Recommends EUA For Covid-19 Vaccines Covovax, Corbevax And Anti-Covid Pill Molnupiravir
- healthNeglected Infectious Diseases May Be Tomorrow's Pandemic: Bharat Biotech Chief Dr Krishna Ella
- healthWill An Omicron-Specific Vaccine Help Control Covid? There's One Key Problem
- healthUnvaccinated People, Children Below 15 Yrs Not Allowed At R-Day Parade: Guidelines
- healthIndian-Origin Scientist Among UBC Researchers Unveil World's 1st Molecular-Level Analysis Of Omicron
- healthOmicron May Not Evade All Monoclonal Antibodies, Lab Study Suggests
- healthHow Are Doctors Coping With COVID Fatigue, As Pandemic Enters 3rd Year? Here's What They Have To Say
- healthCOVID-19: Staying At Isolation Facility Not Mandatory For Foreign Arrivals Testing Positive
- health60% COVID Deaths In 'Third Wave' Among Partially Or Completely Unvaccinated: Max Study